FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

gton, D.C. 20549	OMB APPROVAL

OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Bolzon Bradley J PhD					2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [CRSP]								elationship of eck all applica Director	able)	g Person(s) to Issuer 10% Owner			
(Last) (First) (Middle) C/O CRISPR THERAPEUTICS, INC.				3. Date 06/11/2	of Earliest ²	Transa	action (Mor	nth/D	ay/Year)		Officer (give title below)		Other (spe below)		pecify			
610 MAIN STREET					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBR	IDGE N	ИΑ	02139								Form fil	Form filed by More than One Reporting						
(City)	(State)	(Zip)															
		Ta	able I - Non-I	Derivat	ive S	ecurities	s Acc	quired, I	Disp	oosed o	f, or Be	neficially	Owned					
Date			. Transact Date Month/Day		2A. Deemed Execution Date, if any (Month/Day/Year		, Transaction Disposed Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		Beneficial Owned Fo	i Ily	Form:	Direct Indirect Estr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) o	Price	Reported Transaction (Instr. 3 au	on(s)		1	nstr. 4)		
			Table II - De			curities lls, warr							Owned				'	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Beneficie Owned Followin Reported	re es ally g d	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Shares		Transaction(s (Instr. 4)		?/ 		
Stock Option (Right to	\$43.52	06/11/2019		A	A 15,000 ⁽²⁾		(1)	0	6/11/2029	Common Shares	15,000 ⁽²⁾	\$0.00	15,000 ⁽²⁾		I	See footnote ⁽²⁾		

Explanation of Responses:

- 1. This option was granted on June 11, 2019 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2019; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2020 Annual General Meeting of Shareholders.
- 2. The Reporting Person is a managing member of Versant Venture Management, LLC, the Reporting Person is deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Remarks:

/s/ Michael Esposito, attorney-

06/13/2019

in-fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.